Tema Neuroscience and Mental Health ETF(MNTL.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Tema Neuroscience and Mental Health ETF
MNTL.US
News
View More

Neurocrine Biosciences Reports INGREZZA Achieves Higher VMAT2 Occupancy Than AUSTEDO XR in Head-to-Head Study

Neurocrine Biosciences Inc. has reported the first head-to-head study comparing VMAT2 occupancy between INGREZZA and AUSTEDO XR. Using PET imaging, the study found that INGREZZA achieved higher VMAT2 occupancy at therapeutic doses (83% for 40 mg and 92% for 80 mg) compared to AUSTEDO XR (54% for 24 mg and 70% for 48 mg). These results are significant for treating involuntary movement disorders such as tardive dyskinesia and Huntington’s disease chorea. The findings were presented at a recent meeting.

Reuters·
US
NBIX
-0.72%
Reuters·
US
NBIX
-0.72%

Alnylam Insiders Quietly Unload a Major Chunk of Stock in Synchronized Sell-Off

Several top executives at Alnylam Pharmaceuticals, including CEO Yvonne Greenstreet, have sold significant amounts of company stock in a synchronized sell-off, totaling over $6 million. This insider selling comes amid renewed analyst attention from Oppenheimer, which initiated coverage with a positive outlook on the company's drug Amvuttra, despite concerns about market pressures. Spark's AI Analyst rates ALNY as Neutral, citing strong earnings but high valuation concerns. Alnylam's stock has seen a year-to-date decline of 6.96% with a current market cap of $49 billion.

Tip Ranks·
US
ALNY
0.00%
Tip Ranks·
US
ALNY
0.00%

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine | TEVA Stock News

AJOVY® (fremanezumab-vfrm) has shown significant efficacy in reducing monthly migraine and headache days in children and adolescents with episodic migraine, according to results from the SPACE trial published in the New England Journal of Medicine. The FDA approved AJOVY for preventive treatment in pediatric patients aged 6-17 years weighing 45 kg or more. The trial demonstrated a reduction of 2.5 migraine days and 2.6 headache days compared to placebo, with a consistent safety profile. Teva Pharmaceuticals emphasizes the importance of effective preventive options for this underserved population.

StockTitan·
US
TEVA
-1.82%
StockTitan·
US
TEVA
-1.82%

Argenx receives review from FDA for VYVGART in seronegative gMG

Argenx announced that the FDA has accepted for priority review its supplemental biologics license application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis (gMG). The target action date is set for May 10, 2026. Chief Medical Officer Luc Truyen emphasized the need for improved treatment options for these patients. The application is backed by positive results from the phase 3 ADAPT SERON study, which demonstrated significant improvements in daily living activities for patients treated with VYVGART, with a favorable safety profile.

PharmaTimes·
US
ARGX
-1.63%
PharmaTimes·
US
ARGX
-1.63%

Judge Denies Teva Bid To Pause Paragard Copper Contraceptive Device Lawsuit Trial

A federal judge has denied Teva Pharmaceutical Industries' request to delay the first trial related to its Paragard IUD, which is set to begin on January 20. The trial is part of a larger litigation involving approximately 3,800 lawsuits alleging that the device can fracture during removal, causing injuries. Teva argued that an appeal could end the litigation, but the judge ruled that the trial should proceed. Concerns were raised about Teva's compliance with FDA mandates regarding warning labels. Teva's stock is down 0.21% at $32.72 in premarket trading.

benzinga_article·
US
TEVA
-1.82%
benzinga_article·
US
TEVA
-1.82%
© 2026 Longbridge｜Disclaimer